

**INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN  
CHEMISTRY AND PHARMACEUTICAL SCIENCES**

(p-ISSN: 2348-5213; e-ISSN: 2348-5221)

[www.ijcrps.com](http://www.ijcrps.com)

(A Peer Reviewed, Referred, Indexed and Open Access Journal)

DOI: 10.22192/ijcrps

Coden: IJCROO(USA)

Volume 13, Issue 5- 2026

**Review Article**



DOI: <http://dx.doi.org/10.22192/ijcrps.2026.13.05.003>

**Blood Vessel Disorders: Pathophysiology,  
Clinical Implications, and Therapeutic  
Approaches**

**\*Emmanuel Ifeanyi Obeagu<sup>1, 2</sup>**

<sup>1</sup>Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

<sup>2</sup>The Division of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

\*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, [emmanuelobeagu@yahoo.com](mailto:emmanuelobeagu@yahoo.com),  
ORCID: 0000-0002-4538-0161

Copyright © 2026. Emmanuel Ifeanyi Obeagu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abstract**

Blood vessel disorders encompass a broad spectrum of conditions affecting the arterial, venous, and capillary systems, significantly contributing to global morbidity and mortality. These disorders arise from complex interactions among genetic, environmental, and systemic factors that disrupt vascular integrity and function. Common pathologies include atherosclerosis, vasculitis, thrombosis, aneurysms, and chronic venous insufficiency, each characterized by distinct yet often overlapping pathophysiologic mechanisms such as endothelial dysfunction, inflammation, and aberrant coagulation. The clinical manifestations of blood vessel disorders are heterogeneous, ranging from asymptomatic vascular abnormalities to life-threatening ischemic events, hemorrhage, and organ dysfunction. Accurate and timely diagnosis relies on a combination of clinical evaluation, advanced imaging techniques, laboratory biomarkers, and sometimes histopathological confirmation. Emerging diagnostic tools, including molecular profiling and genetic testing, are enhancing early detection and risk stratification, thereby enabling more personalized and targeted therapeutic interventions.

**Keywords:** Blood Vessel Disorders, Atherosclerosis, Vasculitis, Thrombosis, Vascular Imaging

## Introduction

Blood vessel disorders encompass a wide array of pathological conditions affecting the arterial, venous, and capillary systems, each with unique clinical implications and challenges. The vascular network, composed of arteries, veins, and microvessels, is critical for maintaining tissue perfusion, regulating blood pressure, and facilitating nutrient and waste exchange. Disruption to the integrity or function of these vessels can lead to significant morbidity and mortality worldwide, making vascular diseases a paramount concern in clinical medicine and public health [1-2]. Among blood vessel disorders, atherosclerosis remains the most prevalent and extensively studied condition. It is characterized by the accumulation of lipid-laden plaques within arterial walls, leading to luminal narrowing, ischemia, and ultimately organ dysfunction. The insidious progression of atherosclerosis often results in catastrophic events such as myocardial infarction, stroke, and peripheral artery disease. Importantly, atherosclerosis serves as a common pathological foundation for many cardiovascular diseases, underlying the urgent need for early detection and comprehensive management [3-4].

In contrast, vasculitis comprises a group of immune-mediated disorders that cause inflammation and necrosis of the blood vessel walls. These conditions vary widely in their etiology, clinical manifestations, and prognosis, affecting vessels of different sizes and locations. Vasculitis can cause vessel stenosis, occlusion, or rupture, leading to tissue ischemia or hemorrhage. Despite their relative rarity compared to atherosclerosis, vasculitides pose diagnostic and therapeutic challenges due to their systemic nature and potential for multisystem involvement [5-6]. Thrombosis, defined as the formation of blood clots within vessels, represents another major category of blood vessel disorders. Venous thromboembolism, including deep vein thrombosis and pulmonary embolism, is a leading cause of preventable mortality, often resulting from a combination of endothelial injury, stasis, and hypercoagulability—collectively known as Virchow's triad. Arterial thrombosis, often

superimposed on atherosclerotic plaques, precipitates ischemic events and exacerbates vascular compromise. Understanding the mechanisms of thrombosis is critical to optimizing anticoagulant therapies and improving patient outcomes [7].

Structural abnormalities such as aneurysms and vascular malformations further illustrate the spectrum of blood vessel disorders. Aneurysms, resulting from the weakening and dilation of the vessel wall, can remain asymptomatic for years but carry a high risk of rupture and fatal hemorrhage. Varicose veins and chronic venous insufficiency, resulting from venous valve dysfunction, represent common yet under-recognized conditions that significantly impair quality of life. These disorders highlight the importance of both preventative measures and timely surgical intervention [8]. The pathophysiology of blood vessel disorders is complex and multifactorial, often involving interplay among genetic predisposition, environmental risk factors, systemic diseases, and lifestyle influences. Endothelial dysfunction is a central theme, precipitating inflammation, oxidative stress, and abnormal vascular remodeling. Advances in molecular biology and vascular imaging have significantly expanded our understanding of these mechanisms, enabling more precise diagnosis and targeted therapeutic strategies. However, many challenges remain, including heterogeneity in clinical presentation, limited access to specialized diagnostic tools, and variability in treatment responses [9-10].

## Aim

This review aims to provide a comprehensive overview of blood vessel disorders, focusing on their underlying pathophysiology, clinical manifestations, diagnostic challenges, and current therapeutic strategies.

## Pathophysiology of Blood Vessel Disorders

Blood vessel disorders arise from intricate disruptions in vascular structure and function, driven by a complex interplay of genetic,

molecular, and environmental factors. The vascular endothelium—the innermost cellular lining of blood vessels—plays a central role in maintaining vascular homeostasis by regulating vasomotor tone, hemostasis, inflammatory responses, and permeability. Endothelial dysfunction is widely recognized as a critical initiating event in the pathogenesis of many vascular diseases. Triggered by factors such as hypertension, hyperlipidemia, smoking, and diabetes, endothelial injury leads to impaired nitric oxide bioavailability, oxidative stress, and a pro-inflammatory state that primes the vessel wall for pathological remodeling [11-12].

In occlusive diseases like atherosclerosis, endothelial injury permits the subendothelial accumulation of low-density lipoproteins (LDL), which undergo oxidative modification and incite an inflammatory cascade. This promotes the recruitment of monocytes and T-lymphocytes, transforming monocytes into macrophages that engulf oxidized LDL to become foam cells—the hallmark of early atherosclerotic plaques. The resultant chronic inflammation stimulates smooth muscle cell proliferation and extracellular matrix deposition, leading to plaque progression and arterial wall thickening. Plaque instability, driven by enzymatic degradation and neovascularization, predisposes to rupture and acute thrombotic events such as myocardial infarction or stroke [13-14].

Inflammatory vessel disorders, typified by vasculitis, involve immune-mediated damage to the blood vessel wall. These disorders can affect any vessel size and are characterized by infiltration of immune cells, complement activation, and cytokine release, culminating in vessel wall necrosis, fibrosis, or aneurysm formation. The resultant luminal narrowing compromises blood flow and precipitates ischemic injury to downstream tissues. Similarly, thrombotic disorders reflect a disruption of Virchow’s triad—endothelial injury, stasis or turbulent blood flow, and hypercoagulability—that together create a prothrombotic milieu. The interplay of these factors culminates in intravascular clot formation, potentially occluding vessels and causing ischemic damage [15-16]. Structural anomalies such as aneurysms are rooted in defects of the extracellular matrix and smooth muscle cells within the vascular media, often exacerbated by chronic inflammation and proteolytic enzyme activity. These changes weaken the vessel wall, leading to localized dilation and heightened risk of rupture. Collectively, these pathophysiological mechanisms highlight the dynamic and multifaceted nature of blood vessel disorders, underscoring the importance of early detection and targeted therapeutic intervention to mitigate progression and adverse clinical outcomes [17-18] (Table 1).

**Table 1: Pathophysiology of Blood Vessel Disorders**

Disorder Category	Key Pathophysiological Mechanisms	Core Processes Involved	Representative Conditions
<b>Endothelial Dysfunction</b>	Reduced nitric oxide (NO) bioavailability, oxidative stress, impaired vasomotor regulation	Inflammation, leukocyte adhesion, increased permeability, prothrombotic state	Atherosclerosis, hypertension, diabetic vasculopathy
<b>Atherosclerotic Disease</b>	Lipid accumulation, foam cell formation, plaque development and instability	Chronic inflammation, endothelial injury, smooth muscle proliferation, extracellular matrix remodeling	Coronary artery disease, PAD, carotid stenosis
<b>Vascular Inflammation (Vasculitis)</b>	Autoimmune-mediated endothelial damage, immune complex deposition, necrosis of vessel wall	Cytokine-driven inflammation, fibrinoid necrosis, vascular obstruction or aneurysm formation	ANCA-associated vasculitis, Takayasu arteritis, giant cell arteritis

<b>Arterial Remodeling and Stiffness</b>	Medial hypertrophy, collagen deposition, elastin fragmentation	Increased vascular resistance, compliance, perfusion	Hypertension, aging-related vascular disease
<b>Aneurysm Formation</b>	Degradation of extracellular matrix, loss of elastin and collagen, smooth muscle cell apoptosis	Vessel wall weakening, dilation, risk of rupture	Abdominal aortic aneurysm, thoracic aneurysm
<b>Thrombosis (Arterial and Venous)</b>	Virchow's triad: endothelial injury, stasis, hypercoagulability	Platelet activation, fibrin clot formation, vessel occlusion	DVT, PE, myocardial infarction, stroke
<b>Microvascular Dysfunction</b>	Capillary basement membrane thickening, endothelial swelling, impaired autoregulation	Tissue ischemia, leakage, altered nutrient exchange	Diabetic microangiopathy, hypertensive microangiopathy
<b>Structural Genetic Disorders</b>	Mutations affecting connective tissue or vascular integrity	Defective collagen/elastin, abnormal matrix synthesis, vessel fragility	Marfan syndrome, Ehlers-Danlos syndrome, hereditary hemorrhagic telangiectasia
<b>Venous Valve Dysfunction</b>	Loss of valvular competence, venous hypertension	Venous dilation, edema, inflammation, skin changes	Chronic venous insufficiency, venous ulcers
<b>Microthrombotic Disorders</b>	Dysregulated coagulation, endothelial activation, ADAMTS13 deficiency	Widespread microvascular thrombosis, organ dysfunction	TTP, DIC, complement-mediated microangiopathy

### Clinical Manifestations of Blood Vessel Disorders

Blood vessel disorders present with a wide spectrum of clinical manifestations, reflecting the diverse anatomical locations, vessel sizes, and underlying pathophysiological mechanisms involved. The symptoms can range from subtle, non-specific signs to acute, life-threatening events, making clinical recognition both challenging and critical for early intervention[19]. In arterial disorders such as atherosclerosis, clinical presentation is often related to ischemia resulting from luminal narrowing or occlusion. Patients may experience angina pectoris due to coronary artery involvement, intermittent claudication when peripheral arteries are affected, or transient ischemic attacks and strokes in cases of cerebral artery compromise. These ischemic symptoms typically develop insidiously and progress over time, underscoring the need for high clinical vigilance. In some cases, the first manifestation

may be sudden and catastrophic, such as myocardial infarction or ischemic stroke [20].

Aneurysmal disease frequently remains clinically silent until complications arise. The gradual dilation of arterial walls can be asymptomatic, but rupture results in abrupt, severe symptoms including intense pain, hypotension, and hemorrhagic shock—constituting a vascular emergency. Likewise, vasculitis, characterized by inflammation of the vessel wall, manifests variably depending on the size and location of affected vessels. Systemic symptoms such as fever, malaise, and weight loss may precede organ-specific ischemic manifestations including skin ulcers, neuropathy, or renal impairment, often complicating diagnosis [21].

Venous disorders exhibit distinct clinical features primarily related to impaired venous return and increased venous pressure. Deep vein thrombosis presents with limb swelling, pain, erythema, and tenderness, while chronic venous insufficiency

manifests with edema, skin changes like hyperpigmentation or lipodermatosclerosis, and venous ulcers. The risk of pulmonary embolism adds a potentially fatal dimension to venous thromboembolism, necessitating prompt recognition and treatment. Varicose veins, although often considered a cosmetic issue, can cause discomfort, pruritus, and heaviness, impacting quality of life significantly [22]. Capillary-level involvement in conditions such as microangiopathies may produce symptoms ranging from petechiae and purpura to end-organ damage due to microvascular occlusion. In summary, the clinical manifestations of blood vessel disorders are varied and multifaceted, requiring a thorough history and physical examination to guide appropriate diagnostic evaluation. Early recognition of these symptoms is vital for preventing irreversible tissue injury and improving patient outcomes [23-25].

### **Diagnostic Approaches of Blood Vessel Disorders**

Accurate diagnosis of blood vessel disorders is paramount to guide effective treatment and improve patient outcomes, given the broad clinical spectrum and overlapping presentations of vascular pathologies. A thorough diagnostic evaluation integrates clinical assessment, laboratory investigations, and advanced imaging techniques to characterize the nature, location, and severity of vascular involvement [26-27]. Clinical evaluation remains the cornerstone, beginning with a detailed history and physical examination to identify symptoms such as pain, swelling, ischemia, or signs of systemic inflammation. Specific attention to risk factors—hypertension, diabetes, smoking, family history, and autoimmune conditions—helps stratify the likelihood of particular vascular diseases. Physical examination may reveal palpable masses, bruits, diminished pulses, skin changes, or venous engorgement, providing essential clues to underlying pathology [28-29].

Laboratory investigations are tailored to the suspected disorder. Inflammatory markers such as

erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are elevated in vasculitis and systemic inflammatory conditions. Coagulation profiles, including D-dimer levels and thrombophilia panels, assist in diagnosing thrombotic events. Autoantibody testing and complement levels may be indicated in autoimmune-mediated vasculitides. Additionally, emerging biomarkers and molecular assays hold promise for early detection and disease monitoring [30-31]. Imaging modalities are indispensable for visualizing vascular anatomy and assessing functional impairment. Doppler ultrasound is a non-invasive, first-line tool that evaluates blood flow dynamics, detects vessel narrowing or occlusion, and identifies thrombi in both arterial and venous systems. Computed tomography angiography (CTA) and magnetic resonance angiography (MRA) provide high-resolution images of vessel walls and lumens, enabling precise delineation of aneurysms, stenoses, and inflammatory changes. In selected cases, conventional catheter-based angiography remains the gold standard, offering diagnostic precision combined with therapeutic potential [32].

Complementary techniques such as positron emission tomography (PET) can detect metabolic activity in inflamed vessels, aiding in the diagnosis and monitoring of large-vessel vasculitis. Tissue biopsy, though invasive, is often essential for definitive diagnosis in suspected vasculitis or malignancy involving vessels, allowing histopathological confirmation and subclassification [33]. In recent years, advances in molecular imaging and genetic testing are revolutionizing vascular diagnostics. These technologies facilitate personalized risk assessment and enable targeted therapy by identifying specific molecular signatures of vascular disease. Overall, a multimodal, patient-centered diagnostic approach is critical to unravel the complexity of blood vessel disorders and tailor interventions that optimize clinical outcomes [34-35].

## Therapeutic Strategies of Blood Vessel Disorders

Effective management of blood vessel disorders necessitates a multifaceted therapeutic approach tailored to the underlying pathology, disease severity, and patient-specific factors. Central to treatment is the modulation of key pathogenic processes—endothelial dysfunction, inflammation, thrombosis, and structural vascular damage—to prevent progression and minimize complications. Contemporary therapeutic strategies encompass lifestyle interventions, pharmacologic agents, surgical procedures, and emerging targeted therapies, collectively aimed at restoring vascular integrity and optimizing clinical outcomes [36]. Lifestyle modification forms the cornerstone of both primary prevention and adjunctive therapy in blood vessel disorders. Smoking cessation, regular physical activity, dietary optimization, and strict control of comorbidities such as hypertension, diabetes mellitus, and hyperlipidemia are critical in mitigating risk factors that potentiate vascular injury. These measures not only reduce the incidence of atherosclerotic disease but also improve the efficacy of pharmacologic treatments [37].

Pharmacotherapy is highly individualized, reflecting the heterogeneity of blood vessel disorders. Antiplatelet agents and statins are mainstays in the management of atherosclerosis, reducing thrombotic risk and stabilizing plaques. Anticoagulants play a pivotal role in preventing and treating venous thromboembolism, while immunosuppressive drugs such as corticosteroids and biologics are indispensable in vasculitis, targeting aberrant immune responses that drive vessel inflammation. Advances in drug development have introduced novel agents, including PCSK9 inhibitors for aggressive lipid lowering and targeted monoclonal antibodies that modulate specific inflammatory pathways, heralding a new era of precision medicine [38-39]. Surgical and endovascular interventions remain essential, particularly in cases of critical vessel occlusion, aneurysm repair, or symptomatic varicose veins. Techniques such as

angioplasty, stenting, bypass grafting, and minimally invasive endovenous ablation are selected based on anatomical considerations and patient comorbidities. These procedures have evolved to become less invasive with improved safety profiles, significantly enhancing patient recovery and quality of life [40].

Emerging therapeutic modalities are focused on vascular regeneration and molecular targeting. Experimental approaches utilizing stem cell therapy and angiogenic factors aim to restore damaged endothelium and promote neovascularization. Immunotherapy, including checkpoint inhibitors and biologics, is under investigation for immune-mediated vasculopathies. Furthermore, the integration of genetic and molecular diagnostics is facilitating personalized treatment regimens, enabling clinicians to predict therapeutic responses and tailor interventions accordingly [41-42].

## Endothelial Glycocalyx Research: A New Frontier in Vascular Protection

Recent discoveries highlight the endothelial glycocalyx—a carbohydrate-rich layer lining the vasculature—as a critical regulator of vascular integrity. Traditionally underappreciated, the glycocalyx is now recognized as a dynamic interface modulating shear stress sensing, permeability control, and leukocyte adhesion. Emerging evidence indicates that its degradation precedes overt endothelial dysfunction in conditions such as sepsis, diabetes, and atherosclerosis. Biomarkers such as syndecan-1 and heparan sulfate fragments can now quantify glycocalyx injury, offering opportunities for early disease detection. Therapeutic strategies, including hydrocortisone, albumin-based restoration, and engineered glycocalyx-mimetic polymers, are being explored to reinforce vascular resilience and limit microvascular failure [43].

## Vascular Aging and Senolytic Therapies

Vascular aging is increasingly understood as a biologically programmable process rather than an

inevitable decline. Cellular senescence within endothelial and smooth muscle cells contributes to arterial stiffening, chronic inflammation, and impaired regeneration. Breakthroughs in senolytic agents—drugs that selectively eliminate senescent cells—have shown promise in restoring vascular function in preclinical studies. Compounds such as dasatinib–quercetin and BCL-2 inhibitors reduce the senescence-associated secretory phenotype (SASP), improving arterial compliance and microvascular perfusion. These discoveries open pathways for potential therapies targeting age-related vascular diseases rather than merely their symptoms [44].

### **Vascular Immunometabolism: Metabolic Programming of Endothelial Function**

Advances in immunometabolism reveal that endothelial cells actively reprogram their metabolic pathways during inflammation and vascular stress. Glycolytic upregulation supports angiogenesis, while fatty acid oxidation governs quiescence and repair. Hyperglycemia, dyslipidemia, and hypoxia disrupt these metabolic programs, amplifying vascular injury. Interventions targeting metabolic checkpoints—AMPK activators, PFKFB3 inhibitors, and mitochondrial stabilizing agents—are emerging as therapeutic options. These findings shift the paradigm from viewing endothelial cells solely as passive barriers to recognizing them as metabolically adaptable regulators of vascular homeostasis [45].

### **Clonal Hematopoiesis and Vascular Risk**

Clonal hematopoiesis of indeterminate potential (CHIP) represents one of the most significant discoveries in modern vascular research. Somatic mutations in hematopoietic stem cells, particularly in TET2, DNMT3A, and ASXL1, create mutant clones that produce pro-inflammatory myeloid cells. These cells accelerate atherosclerosis, thrombosis, and vascular inflammation—*independent of* traditional risk factors. CHIP is now considered a

non-traditional cardiovascular risk factor rivaling smoking and hyperlipidemia in impact. Ongoing studies aim to develop mutation-specific therapies and screening algorithms to mitigate vascular risk in aging populations [46].

### **Extracellular Vesicles and MicroRNAs in Vascular Regulation**

Extracellular vesicles (EVs), including exosomes and microvesicles, are now recognized as potent modulators of vascular biology. EVs carry microRNAs, proteins, and lipids that influence endothelial activation, angiogenesis, and thrombosis. For example, miR-126 enhances vascular repair, whereas miR-155 promotes inflammation and plaque instability. Circulating EVs are being explored as biomarkers for vascular injury, providing early diagnostic insights into diseases such as vasculitis and coronary artery disease. Therapeutically, engineered EVs are being developed as delivery systems capable of targeted molecular modulation of vascular tissues [47].

### **Advances in Vascular Regenerative Therapy**

Regenerative medicine has entered a transformative phase in vascular care. Endothelial progenitor cells (EPCs), once a theoretical concept, are now being evaluated in clinical-grade therapies for ischemia, diabetic ulcers, and refractory vascular obstruction. Tissue-engineered blood vessels created from decellularized scaffolds or stem-cell–derived vascular cells show promise for durable grafting in high-risk surgical patients. Furthermore, exosome-based therapeutics offer a cell-free approach to stimulate angiogenesis, reduce fibrosis, and restore microvascular architecture. These innovations may redefine treatment for patients with critical limb ischemia and advanced microvascular dysfunction [48].

## Artificial Intelligence (AI) and Precision Vascular Medicine

AI-driven diagnostic systems are revolutionizing vascular care. Machine learning algorithms can detect subtle features of plaque vulnerability, aneurysm expansion, and microvascular perfusion abnormalities beyond human visual capacity. Precision imaging tools employing AI-assisted CT and MRI analyses enable individualized risk prediction and early intervention planning. On the therapeutic front, AI-guided robotic endovascular procedures are being refined to enhance precision and reduce complication rates. Predictive modeling is also being utilized to tailor antithrombotic therapy based on patient-specific genomic, metabolic, and imaging data [49-50].

## Novel Anti-inflammatory Agents Targeting Specific Cytokine Pathways

Understanding of cytokine-driven vascular inflammation has advanced significantly. Targeted agents such as IL-1 $\beta$  inhibitors (canakinumab) and IL-6 receptor blockers (tocilizumab) have demonstrated vascular protective effects in selected populations. The CANTOS trial, a landmark study, provided direct evidence that anti-inflammatory therapy reduces cardiovascular events independently of lipid lowering. Newer molecules targeting GM-CSF, TNF- $\alpha$  subpathways, and the NLRP3 inflammasome are currently under investigation, offering more precise suppression of vascular inflammation with fewer systemic adverse effects [51].

## Conclusion

Blood vessel disorders encompass a diverse and complex group of conditions that significantly contribute to the global burden of cardiovascular morbidity and mortality. Their multifaceted pathophysiology—spanning endothelial dysfunction, inflammation, thrombosis, and structural vessel abnormalities—underlines the necessity for a comprehensive and nuanced

approach to diagnosis and management. Early identification of these disorders remains challenging but is crucial for preventing life-threatening complications such as myocardial infarction, stroke, aneurysm rupture, and venous thromboembolism. Advances in diagnostic technologies, including high-resolution vascular imaging and molecular biomarkers, have revolutionized the ability to detect and characterize vascular pathology with greater precision. These tools enable clinicians to stratify patient risk more effectively and tailor therapeutic interventions accordingly. Moreover, the emergence of targeted pharmacotherapies and immunomodulatory agents reflects a paradigm shift toward personalized medicine, offering hope for improved efficacy and reduced treatment-related morbidity.

## Conflicts of Interest

The authors declare no conflict of interest

## Sources of Funding

No fund was received to write this review paper

## Ethical Approval

Not applicable

## Abbreviations

AAA – Abdominal Aortic Aneurysm  
ADAMTS13 – A Disintegrin and Metalloprotease with Thrombospondin Type 1 Motif, Member 13  
ANCA – Antineutrophil Cytoplasmic Antibody  
CAD – Coronary Artery Disease  
CTA – Computed Tomography Angiography  
DIC – Disseminated Intravascular Coagulation  
DOACs – Direct Oral Anticoagulants  
DVT – Deep Vein Thrombosis  
ECM – Extracellular Matrix  
ESR – Erythrocyte Sedimentation Rate  
EVAR – Endovascular Aneurysm Repair  
GCA – Giant Cell Arteritis  
LDL – Low-Density Lipoprotein  
MRA – Magnetic Resonance Angiography  
NO – Nitric Oxide

PAD – Peripheral Artery Disease  
PCSK9 – Proprotein Convertase Subtilisin/Kexin  
Type 9  
PE – Pulmonary Embolism  
PET-CT – Positron Emission Tomography–  
Computed Tomography  
TTP – Thrombotic Thrombocytopenic Purpura  
VCAM-1 – Vascular Cell Adhesion Molecule-1  
VTE – Venous Thromboembolism

## References


1. Nwokoye PN, Abilez OJ. Blood vessels in a dish: the evolution, challenges, and potential of vascularized tissues and organoids. *Front Cardiovasc Med.* 2024; 11:1336910. doi: 10.3389/fcvm.2024.1336910.
2. Yetkin E, Ozturk S. Dilating Vascular Diseases: Pathophysiology and Clinical Aspects. *Int J Vasc Med.* 2018; 2018:9024278. doi: 10.1155/2018/9024278.
3. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K, Benito-Vicente A, Martín C. Pathophysiology of Atherosclerosis. *Int J Mol Sci.* 2022;23(6):3346. doi: 10.3390/ijms23063346.
4. Morrison AM, Sullivan AE, Aday AW. Atherosclerotic Disease: Pathogenesis and Approaches to Management. *Med Clin North Am.* 2023;107(5):793-805. doi: 10.1016/j.mcna.2023.04.004.
5. Guillevin L, Dörner T. Vasculitis: mechanisms involved and clinical manifestations. *Arthritis Res Ther.* 2007;9 Suppl 2(Suppl 2): S9. doi: 10.1186/ar2193.
6. Martins-Martinho J, Dourado E, Khmelinskii N, Espinosa P, Ponte C. Localized Forms of Vasculitis. *Curr Rheumatol Rep.* 2021;23(7):49. doi: 10.1007/s11926-021-01012-y.
7. Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien MG, Naidu S, Oklu R. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. *CardiovascDiagnTher.* 2017;7(Suppl 3): S276-S284. doi: 10.21037/cdt.2017.09.01.
8. Yetkin E, Ozturk S. Dilating Vascular Diseases: Pathophysiology and Clinical Aspects. *Int J Vasc Med.* 2018; 2018:9024278. doi: 10.1155/2018/9024278.
9. Ambrosino P, Bachetti T, D'Anna SE, Galloway B, Bianco A, D'Agnano V, Papa A, Motta A, Perrotta F, Maniscalco M. Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. *J Cardiovasc Dev Dis.* 2022;9(5):136. doi: 10.3390/jcdd9050136.
10. Ortega MA, Fraile-Martínez O, García-Montero C, Álvarez-Mon MA, Chaowen C, Ruiz-Grande F, Pekarek L, Monserrat J, Asúnsolo A, García-Honduvilla N, Álvarez-Mon M, Bujan J. Understanding Chronic Venous Disease: A Critical Overview of Its Pathophysiology and Medical Management. *J Clin Med.* 2021;10(15):3239. doi: 10.3390/jcm10153239.
11. Pluta W, Lubkowska A, Dudzińska W. Vascular Endothelium in Health and Disease: Structure, Function, Assessment and Role in Metabolic Disorders. *Vasc Health Risk Manag.* 2025; 21:729-747. doi: 10.2147/VHRM.S519426.
12. Sandoo A, van Zanten JJ, Metsios GS, Carroll D, Kitas GD. The endothelium and its role in regulating vascular tone. *Open Cardiovasc Med J.* 2010; 4:302-12. doi: 10.2174/1874192401004010302.
13. Jiang H, Zhou Y, Nabavi SM, Sahebkar A, Little PJ, Xu S, Weng J, Ge J. Mechanisms of Oxidized LDL-Mediated Endothelial Dysfunction and Its Consequences for the Development of Atherosclerosis. *Front Cardiovasc Med.* 2022; 9:925923. doi: 10.3389/fcvm.2022.925923.
14. Maiolino G, Rossitto G, Caielli P, Bisogni V, Rossi GP, Calò LA. The role of oxidized low-density lipoproteins in atherosclerosis: the myths and the facts. *Mediators Inflamm.* 2013; 2013:714653. doi: 10.1155/2013/714653.
15. Guillevin L, Dörner T. Vasculitis: mechanisms involved and clinical manifestations. *Arthritis Res Ther.* 2007;9 Suppl 2(Suppl 2): S9. doi: 10.1186/ar2193.
16. Ramirez GA, Maugeri N, Sabbadini MG, Rovere-Querini P, Manfredi AA. Intravascular immunity as a key to systemic

- vasculitis: a work in progress, gaining momentum. *Clin Exp Immunol.* 2014;175(2):150-66. doi: 10.1111/cei.12223.
17. Khoury MK, Stranz AR, Liu B. Pathophysiology of Aortic Aneurysms: Insights from Animal Studies. *Cardiol Cardiovasc Med.* 2020;4(4):498-514. doi: 10.26502/fccm.92920146.
  18. Quintana RA, Taylor WR. Cellular Mechanisms of Aortic Aneurysm Formation. *Circ Res.* 2019;124(4):607-618. doi: 10.1161/CIRCRESAHA.118.313187.
  19. Yetkin E, Ozturk S. Dilating Vascular Diseases: Pathophysiology and Clinical Aspects. *Int J Vasc Med.* 2018; 2018:9024278. doi: 10.1155/2018/9024278.
  20. Morrison AM, Sullivan AE, Aday AW. Atherosclerotic Disease: Pathogenesis and Approaches to Management. *Med Clin North Am.* 2023;107(5):793-805. doi: 10.1016/j.mcna.2023.04.004.
  21. Kannel WB, Evans JC, Piper S, Murabito JM. Angina pectoris is a stronger indicator of diffuse vascular atherosclerosis than intermittent claudication: Framingham study. *J Clin Epidemiol.* 2008;61(9):951-7. doi: 10.1016/j.jclinepi.2007.10.025.
  22. Matta AG, Yaacoub N, Nader V, Moussallem N, Carrie D, Roncalli J. Coronary artery aneurysm: A review. *World J Cardiol.* 2021;13(9):446-455. doi: 10.4330/wjc.v13.i9.446.
  23. Ornowska S, Chojnowski M, Felis-Giemza A, Dudek Ł, Olesińska M. Microvascular damage - a marker of specific organ involvement in mixed connective tissue disease? *Reumatologia.* 2021;59(2):115-120. doi: 10.5114/reum.2021.105457. Epub 2021 Apr 27. PMID: 33976466; PMCID: PMC8103405.
  24. Lamadrid-Zertuche AC, Garza-Rodríguez V, Ocampo-Candiani JJ. Pigmented purpura and cutaneous vascular occlusion syndromes. *An Bras Dermatol.* 2018;93(3):397-404. doi: 10.1590/abd1806-4841.20187459.
  25. Lambova SN. Microangiopathy in Rheumatic Diseases. *Life (Basel).* 2023 ;13(2):491. doi: 10.3390/life13020491.
  26. Zhang P, Li Y, Li X, Wang Y, Lin H, Zhang N, Li W, Jing L, Jiao M, Luo X, Hou Y. Shedding light on vascular imaging: the revolutionary role of nanotechnology. *J Nanobiotechnology.* 2024;22(1):757. doi: 10.1186/s12951-024-03042-x.
  27. Wen F, Liu Y, Wang H. Clinical Evaluation Tool for Vascular Health-Endothelial Function and Cardiovascular Disease Management. *Cells.* 2022;11(21):3363. doi: 10.3390/cells11213363.
  28. Jin X, Liu Y, Jia W, Xu R, Guan X, Cui M, Zhang H, Wu H, Wei L, Qi X. Association Between Systemic Immune-Inflammatory Indices and Severity of Coronary Artery Lesions in Patients with Coronary Artery Disease in Different Glucose Metabolic States. *J Inflamm Res.* 2025; 18:3295-3309. doi: 10.2147/JIR.S507696.
  29. American Diabetes Association Professional Practice Committee. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022. *Diabetes Care.* 2022;45(Suppl 1): S46-S59. doi: 10.2337/dc22-S004.
  30. Monach PA. Biomarkers in vasculitis. *Curr Opin Rheumatol.* 2014;26(1):24-30. doi: 10.1097/BOR.0000000000000009.
  31. Bitik B, Mercan R, Tufan A, Tezcan E, Küçük H, İlhan M, Öztürk MA, Haznedaroğlu S, Göker B. Differential diagnosis of elevated erythrocyte sedimentation rate and C-reactive protein levels: a rheumatology perspective. *Eur J Rheumatol.* 2015;2(4):131-134. doi: 10.5152/eurjrheum.2015.0113.
  32. Babington EA, Amedu C, Anyasor E, Reeve R. Non-contrast ultrasound assessment of blood flow in clinical practice. *J Ultrason.* 2024;24(98):1-9. doi: 10.15557/jou.2024.0029.
  33. Tomelleri A, Campochiaro C, Grayson PC, Quinn KA. The Role of FDG-PET in the Diagnosis and Monitoring of Large-Vessel Vasculitis. *Curr Rheumatol Rep.* 2025;27(1):40. doi: 10.1007/s11926-025-01204-w.

34. Wang Y, Yang W, Li Y. Research advances on artificial intelligence assisted diagnosis and risk assessment in cardiovascular disease using retinal imaging. *Front Cardiovasc Med.* 2025; 12:1615857. doi: 10.3389/fcvm.2025.1615857.
35. Agha RA, Mathew G, Rashid R, Kerwan A, Al-Jabir A, Sohrabi C, Franchi T, Nicola M, Agha M and TITAN Group. Transparency in the Reporting of Artificial Intelligence – The TITAN Guideline. *Premier Journal of Science* 2025; 10:100082 DOI: <https://doi.org/10.70389/PJS.100082>
36. Netala VR, Teertam SK, Li H, Zhang Z. A Comprehensive Review of Cardiovascular Disease Management: Cardiac Biomarkers, Imaging Modalities, Pharmacotherapy, Surgical Interventions, and Herbal Remedies. *Cells.* 2024;13(17):1471. doi: 10.3390/cells13171471.
37. Han B, Lee GB, Yoon J, Kim YH. Lifestyle interventions for hypertension management in primary care: a narrative review. *Ewha Med J.* 2025;48(4): e56. doi: 10.12771/emj.2025.00850.
38. Ozyuncu N. Antiplatelet Therapy in Heart Disease. *Rev Cardiovasc Med.* 2025;26(6):36522. doi: 10.31083/RCM36522.
39. Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl): e89S-e119S. doi: 10.1378/chest.11-2293.
40. Khan A, Sorour AA, E Anton G, Lyden SP, Kirksey L. Venous Insufficiency: Endovascular and Surgical Treatment. *CurrCardiol Rep.* 2025;27(1):67. doi: 10.1007/s11886-024-02155-x.
41. Roolfs L, Hubertus V, Spinnen J, Shopperly LK, Fehlings MG, Vajkoczy P. Therapeutic Approaches Targeting Vascular Repair After Experimental Spinal Cord Injury: A Systematic Review of the Literature. *Neurospine.* 2022;19(4):961-975. doi: 10.14245/ns.2244624.312.
42. Leeper NJ, Hunter AL, Cooke JP. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells. *Circulation.* 2010;122(5):517-26. doi: 10.1161/CIRCULATIONAHA.109.881441.
43. Reitsma S, Slaaf DW, Vink H, van Zandvoort MA, oudeEgbrink MG. The endothelial glycocalyx: composition, functions, and visualization. *Pflugers Arch.* 2007;454(3):345-59. doi: 10.1007/s00424-007-0212-8.
44. Picos A, Seoane N, Campos-Toimil M, Viña D. Vascular senescence and aging: mechanisms, clinical implications, and therapeutic prospects. *Biogerontology.* 2025;26(3):118. doi: 10.1007/s10522-025-10256-5.
45. Zhili G, Zhimin G, Nenghua Z. Role of vascular endothelial dysfunction and metabolic eprogramming of immune cells in the development and ogression of atherosclerosis. *Front Physiol.* 2025; 16:1624225. doi: 10.3389/fphys.2025.1624225.
46. Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): Linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. *J Mol Cell Cardiol.* 2021; 161:98-105. doi: 10.1016/j.yjmcc.2021.07.004.
47. Patel S, Guo MK, Abdul Samad M, Howe KL. Extracellular vesicles as biomarkers and modulators of atherosclerosis pathogenesis. *Front Cardiovasc Med.* 2023; 10:1202187. doi: 10.3389/fcvm.2023.1202187.
48. Chong MS, Ng WK, Chan JK. Concise Review: Endothelial Progenitor Cells in Regenerative Medicine: Applications and Challenges. *Stem Cells Transl Med.* 2016;5(4):530-8. doi: 10.5966/sctm.2015-0227.
49. Zhang H, Ma W, Zhou X, Zhao Z, Zhang R, Bai H, Huang C, Wang Y. Artificial Intelligence in Cerebrovascular Disease Management: A Comprehensive Review of Risk Prediction, Diagnosis, Therapeutic Optimization, and Clinical Translation. *Vasc*

Health Risk Manag. 2025; 21:949-964. doi: 10.2147/VHRM.S555592.

50. Pomozi E, Quintero-Peña C, Csore J, Crichton A, Wang G, Karmonik C, Roy T. Innovations in MRI and AI Integration for Vascular Plaque Evaluation and Overview of Deep Learning Techniques in Peripheral Vascular Disease. Methodist Debaquey Cardiovasc J. 2025;21(5):71-80. doi: 10.14797/mdcvj.1642.
51. Bora R, Kılıç AT, Toprak B. Atherosclerosis and Inflammation: Are the Rules of the Game Changing with Biological Therapies? J Inflamm Res. 2025; 18:9811-9822. doi: 10.2147/JIR.S531345.

<b>Access this Article in Online</b>	
	Website: <a href="http://www.ijcrcps.com">www.ijcrcps.com</a>
	Subject: <a href="#">Haematology</a>
<b>Quick Response Code</b>	
DOI: <a href="https://doi.org/10.22192/ijcrcps.2026.13.05.003">10.22192/ijcrcps.2026.13.05.003</a>	

**How to cite this article:**

Emmanuel Ifeanyi Obeagu. (2026). Blood Vessel Disorders: Pathophysiology, Clinical Implications, and Therapeutic Approaches. Int. J. Curr. Res. Chem. Pharm. Sci. 13(5): 21-32.  
DOI: <http://dx.doi.org/10.22192/ijcrcps.2026.13.05.003>